Autoimmune disorders have risen to be among the most prevalent chronic diseases across
the globe, affecting approximately 5–7% of the population. As autoimmune diseases steadily …

The development of vaccines has entered a new era with the advent of nanotechnology,
particularly through the utilization of nanoparticles. This review focuses on the role of …

Pre-eclampsia is a placental disorder that affects 3–5% of all pregnancies and is a leading
cause of maternal and fetal morbidity worldwide 1, 2. With no drug available to slow disease …

There is a clinical need to develop lipid nanoparticles (LNPs) to deliver congenital therapies
to the fetus during pregnancy. The aim of these therapies is to restore normal fetal …

Chimeric antigen receptor T cell (CAR-T) therapy has emerged as a revolutionary approach
in the treatment of malignancies. Despite its remarkable successes, this field continues to …

Abstract Design of inhalable mRNA therapeutics is promising because local administration
in the respiratory tract is minimally invasive and induces a local response. However, several …

Clinically approved therapeutics for obstetric conditions are extremely limited, with over 80%
of drugs lacking appropriate labeling information for pregnant individuals. The pathology for …

Lipid nanoparticle (LNP) formulation plays a vital role in RNA vaccine delivery. However,
further optimisation of self-amplifying RNA (saRNA) vaccine formulation could help enhance …

Cardiovascular diseases (CVDs) are the leading cause of global mortality among non-
communicable diseases. Current cardiac regeneration treatments have limitations and may …

The potential of messenger RNA (mRNA) as a therapeutic tool for treating diseases has
garnered considerable interest, especially in the wake of the successful creation of mRNA …